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RESUMO  
O sistema CRISPR (do inglês: clustered regularly interspaced short palindromic 
repeats) faz parte de um processo de imunidade adquirida existente nas bactérias, sendo 
constituído por sequencias de bases de ácido desoxirribonucleico (ADN) curtas e repetitivas que 
fornecem uma imunidade adquirida contra vírus e plasmídeos tendo como alvo o ácido nucleico 
dos invasores de uma forma específica. Os loci CRISPR consistem num arranjo de sequências 
repetitivas curtas de aproximadamente 30-40 pares de bases e parcialmente palindrómico, 
intervaladas por sequências de 'espaçador' igualmente curtas de origem viral ou de plasmídeo. 
Os espaçadores fornecem um registo genético de uma infeção anterior, o que permite ao 
hospedeiro prevenir futuras invasões do mesmo agente infecioso.  
A Cas9 é uma endonuclease de ADN, multifuncional, com aproximadamente 1,368 
aminoácidos. Esta endonuclease cliva ADN de cadeia dupla, 3 pares de bases a montante do 
Motivo Adjacente ao Protoespaçador (do inglês: Protospacer adjacent motif, PAM) através de 
dois domínios distintos de nucleases. Tem um domínio de nuclease tipo HNH que cliva a cadeia 
de DNA complementar à sequência guia de ácido ribonucleico (ARN), também conhecida como 
a cadeia alvo, e um domínio de nuclease tipo RuvC responsável por clivar a cadeia de DNA oposta 
à cadeia complementar. Adicionalmente, a Cas9 também participa na maturação do ácido 
ribonucleico CRISPR (do inglês: CRISPR ribonucleic acid, crRNA) e da aquisição do espaçador. 
A edição de genoma é um tipo de engenharia genética na qual ADN é inserido, deletado 
ou substituído no genoma de organismos celulares através de nucleases programáveis e 
altamente específicas como a CRISPR/Cas9. O sistema de CRISPR/Cas9 depende de ARNs 
pequenos como o crRNA, crRNA de ativação em trans (do inglês: trans-activating crRNA, 
tracrRNA) e ARN guia (do inglês: single-guide RNA, sgRNA) para clivagem de sequências 
específicas de ADN. A Cas9 necessita apenas de uma sequência de 20 nucleótidos no sgRNA que 
se emparelha com os pares de bases do ADN alvo e a presença de um PAM adjacente à região de 
complementaridade. 
As quebras de cadeias duplas induzidas por nucleases podem ser reparadas por ligação 
de extremidades não homólogas (do inglês: Non-Homologous End-Joining, NHEJ) e por reparação 
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direcionada por homologia (do inglês: Homology Directed Repair, HDR). As modificações 
baseadas em NHEJ são propensas a erros e incluem pequenas inserções ou deleções (indels). Por 
outro lado, as modificações baseadas em HDR usam um modelo de ADN nativo ou desenhado 
para substituir o alelo alvo por uma sequência desenhada pelo processo de recombinação. 
Existem outras vias de reparação de ADN que também podem produzir edições de genoma. Na 
ausência de um modelo de reparação, as quebras de cadeias duplas são religadas através do 
processo NHEJ, onde ocorrem mutações indel. No entanto, pode ser fornecido um modelo de 
reparação para promover o caminho HDR, que permite alta fidelidade e edição precisa. 
Uma vez que o CRISPR acompanhado pela Cas9 pode ser programado para editar 
qualquer local de interesse no genoma, torna-se possível a correção de erros e mutações que o 
genoma possa ter sofrido, e ainda ativar ou desativar genes em células e organismos, de forma 
eficaz, rápida e económica. Desta forma, o processo de CRISPR/Cas9 tem sido aplicado em 
diversas áreas de interesse como medicina, biotecnologia, biologia e agricultura para controlar 
por exemplo a transcrição, modificar epigenomas, realizar rastreios genómicos, manipular 
circuitos biológicos facilitando a geração de materiais sintéticos, corrigir mutações genéticas e 
controlar a expressão de genes inteiros.  
Especificamente, este mecanismo tem sido intensamente explorado para aplicação em 
patologias humanas como a investigação dos mecanismos responsáveis de diversas doenças, 
rastreio para descoberta de novos fármacos e desenvolvimento de novas terapias, diagnóstico 
rápido, edição in vitro e in vivo e correção de transmissões hereditárias. Atualmente, o 
CRISPR/Cas9 já tem sido aplicado em doenças sem atual cura clínica de origem viral como o vírus 
da imunodeficiência humana (VIH), vírus Epstein-Barr (VEB), vírus da hepatite B, papilomavírus 
humano (HPV), vírus de John Cunningham (VJC) e o vírus herpes simplex (VHS). Igualmente já 
tem sido utilizado em doenças genéticas sem cura como a talassemia β, fibrose cística, distrofia 
muscular de duchenne e doença de Huntington. A crescente resistência aos antibióticos também 
despoletou interesse na utilização do CRISPR/Cas9 nesta área. Por fim, esta tecnologia tem sido 
utilizada no estudo da área da oncologia visto que esta é uma doença devastadora de origem 
genética que provoca uma em cada seis mortes mundialmente e, infelizmente, o arsenal 
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terapêutico existente para o cancro tem limitações na sua capacidade de cura e muitos efeitos 
adversos relatados incluindo toxicidade. 
Apesar do CRISPR/Cas9 apresentar resultados positivos e promissores em diversas 
patologias, este sistema tem algumas limitações tais como mutações fora de alvo, problemas 
com o sistema de entrega, dependência do PAM e questões éticas que devem ser ultrapassadas 
de modo a que seja possível progredir para estudos clínicos posteriormente.  
Seguramente, o futuro desta nova tecnologia aparenta ser promissor e digno da atenção 
de toda a comunidade científica, visto que poderá possivelmente constituir a resposta ao 
tratamento muitas patologias humanas que neste momento são consideradas incuráveis. 
No primeiro capítulo desta revisão bibliográfica, é apresentada uma breve introdução da 
história do CRISPR desde a primeira vez que foi descrito, passando pela descoberta da sua função 
em bactérias, até ao presente em que este método de edição genética é adaptado para uso 
laboratorial. Posteriormente no mesmo capítulo introdutório, são descritas as estruturas do 
CRISPR e da Cas9 e o seu respetivo mecanismo de ação. Por fim, ainda é descrita a transição da 
sua aplicação na edição do genoma a nível laboratorial que inclui também a comparação do 
CRISPR/Cas9 com os métodos de edição genética anteriores e a discussão sobre o 
desenvolvimento dos diversos métodos de entrega deste sistema ao local de ação pretendido.  
No segundo capítulo são abordadas as aplicações gerais do sistema de edição genética do 
CRISPR/Cas9 em áreas como a medicina, biotecnologia, biologia e agricultura e, mais 
especificamente em algumas patologias humanas de origem viral, genética, bacteriana e ainda 
um subcapítulo dedicado somente às doenças oncológicas. É feita uma breve descrição das 
patologias abordadas, descrevendo a sua origem, o mecanismo responsável pelo desencadear 
da doença, os seus sintomas, assim como o seu tratamento e as limitações associadas e por fim 
a utilização do sistema CRISPR/Cas9 no desenvolvimento de novas terapias. 
No terceiro capítulo são discutidas as limitações desta nova tecnologia incluindo as 
mutações fora de alvo, a sua dependência do PAM, as fragilidades dos métodos de entrega do 
CRISPR/Cas9 e as questões éticas levantadas pelo uso deste método de edição genética.  
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Por fim, no quarto e último capítulo são abordadas as considerações finais deste tema e 
as perspetivas futuras do CRISPR/Cas9. 
Palavras-chave: CRISPR, Cas9, edição do genoma, patologias humanas 
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ABSTRACT  
Clustered regularly interspaced short palindromic repeats (CRISPR) is an adaptive 
immune system of bacteria, of prokaryotic deoxyribonucleic acid (DNA) that contain short, 
repetitive base sequences which mediate acquired immunity by targeting viral DNA and plasmids 
in a sequence-specific manner. Paired with Cas9, a large multi-domain and multifunctional DNA 
endonuclease, this system can be programmed to edit nearly any genomic location of interest 
making it conceivable to correct genome errors while also permitting to relatively easily, quickly 
and at a reduced cost to turn genes on or off in cells and organisms.  
The versatile CRISPR/Cas9 system has been getting increased applications in diverse areas 
such as medicine, biotechnology and biology. Recently, the possibility of using CRISPR/Cas9 in 
several human diseases has been thoroughly investigated as it may reveal to be a valuable 
addition to their therapeutic arsenal, displaying promising results. However, this system also has 
its limitations such as off-target mutations, delivery vehicle problems, PAM dependence and 
raising ethical concerns that must be surpassed in order to consider further its clinical 
applications.  
The future of this new technology certainly seems bright and deserves a great attention 
of the scientific community as it may prove to provide the means to cure many high burden 
diseases currently affecting humanity. 
Chapter one presents an introduction to CRISPR/Cas9, unfolding its history, describing its 
structure and associated mechanism and finally explaining the transition to its use in genome 
editing. In chapter two, the general applications of CRISPR/Cas9 are described as well as its 
specific applications for a defined set of selected diseases affecting mankind that can be targeted 
by this genome editing technique. The current existing limitations are discussed in chapter three 
and finally conclusions and future prospects for CRISPR/Cas9 are presented in a final section, 
chapter four. 
Keywords: CRISPR, Cas9, Genome editing, human pathologies 
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1. INTRODUCTION 
 
Clustered regularly interspaced short palindromic repeats (CRISPR) is an adaptive 
immune system, used by bacteria, through which prokaryotic deoxyribonucleic acid (DNA) that 
contain short, repetitive base sequences mediate acquired immunity by targeting viral DNA and 
plasmids in a sequence-specific manner1. 
CRISPR/Cas9 is the basis of a genome editing technology that allows permanent 
modification of genes within organisms making it conceivable to correct genome errors while 
also permitting, relatively easily, quickly and at a reduced cost, to turn genes on or off in cells and 
organisms. The CRISPR/Cas9 system has been used for several laboratory applications including 
functional genomic screens, live imaging of the cellular genome and rapid generation of both 
cellular and animal models. The potential use of CRISPR/cas9 to edit human genomes would offer 
us the potential to cure any genetic disorder, and it is a promising field that is advancing at a 
noteworthy pace2,3.  
 
1.1 History 
 
The first description of CRISPR was in 1987 from Yoshizumi Ishino who accidently cloned 
part of a CRISPR together with the iap gene, from a genome of Escherichia coli 4. 
Later in 1993 Francisco Mojica at the University of Alicante, Spain, pioneered the studies 
of CRISPR while he was working on Haloferax mediterranei, an archaeal microbe with extreme 
salt tolerance5. Meanwhile, it was discovered that the salt concentration of the growth medium 
seemed to influence how restriction enzymes were cutting the microbial genome, and Mojica 
decided to describe the altered fragments5. In a DNA fragment examined, he found a structure 
with several copies of a palindromic repeated sequence of 30 bases, separated by spacers of 
approximately 36 bases that did not look like any family of repeats previously known. Mojica 
initially named it short regularly spaced repeats (SRSRs), but later it was renamed as CRISPR5.  
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In 2000 Mojica classified interspaced repeat sequences as an exclusive family of repeat 
elements that usually occur in clusters present in 90% of archaea and over 40% of sequenced 
bacteria6. Two years later, Mojica and Jansen created the acronym CRISPR to unify the 
description of microbial genomic loci comprising an interspaced repeat array. At the same time 
Jansen observed several clusters of signature CRISPR-associated system (cas) genes typically 
adjacent to the repeat elements, but its function was still unknown7. 
The first clue regarding the biological function of CRISPR was unearthed in 2005, when 
three distinct research groups nearly concurrently saw that the seemingly random sequences 
separating identical CRISPR repeats showed homology to invasive DNA sequences, such as 
viruses and plasmids8–10. One of the research groups that observed this was Mojica’s group. They 
removed each spacer and inserted it into to the Basic Local Alignment Search Tool (BLAST)11 
program to search for correspondences with any other known DNA sequence. Subsequently, they 
positively identified, in a CRISPR locus from an E. coli strain, one of the spacers which matched 
the sequence of a P1 phage that infected several E. coli strains. However, the strain carrying the 
spacer was known to be resistant to P1 infection. This made it clear for Mojica that this loci must 
encode an adaptive immune system that protected against specific infections 10. Simultaneously, 
Bolotin and colleagues observed that the spacers, all have a similar sequence8 at one end which 
would later end up to be called the protospacer adjacent motif (PAM)12. 
After suggesting CRISPR as an immune system in prokaryotes, the scientific community 
moved on to the demonstration of its biological function. In 2007, Barrangou and his team at 
Danisco (food ingredient company) had available the various pieces required to prove the theory 
that CRISPR is an adaptive immune system. They possessed in silico datasets containing the 
genomes of bacteria encoding diverse CRISPR–Cas systems and the genomes of bacteriophages 
able to infect them, the biological material, including bacterial isolates that carried active CRISPR–
Cas systems and lytic phages that could readily infect these hosts and finally the information from 
the existing literature 13. 
During attempts to develop molecular methods for strain differentiation of Streptococcus 
thermophilus, Barrangou discovered the existence of CRISPR loci. Initially, his team used CRISPR 
sequences to compare numerous S. thermophilus strains and observed the conservation of some 
CRISPR: applications in human pathologies and future prospects 
 
 3 
spacers across groups of strains. Curiously, strains clustered in groups for which the CRISPR 
genotypes associated with phage resistance phenotypes. Also, they noticed that occasionally 
strains that had been isolated at different moments in time did carry additional repeat–spacer 
sequences, suggesting phage-induced and time-dependent variability of CRISPR sequences13. 
Through the comparison of data between sequences of CRISPR loci of industrial strains and phage 
genome sequences, the link between the CRISPR genotype and the phage resistance phenotype 
became noticeable13.  Subsequently, Barrangou and his team started a series of experiments that 
confirmed that CRISPR systems are indeed an adaptive immune system. Using a S. thermophilus 
strain, that was well-characterized for being phage-sensitive, and two bacteriophages, they 
performed genetic selections to isolate bacteria that was resistant to bacteriophages. Instead of 
developing resistance mutations, the resistant strains had acquired DNA sequences of 
bacteriophage origin at their CRISPR loci. Furthermore, the insertion/deletion of multiple spacers 
correlated with increased/decreased resistance, respectively. They also demonstrated that Cas 
genes control spacer acquisition and corresponding phage defense13. 
The S.  thermophilus model1 was the first CRISPR–Cas system in which adaptation13, 
biogenesis of CRISPR ribonucleic acids (crRNAs)14,15 and interference16 were characterized in 
native conditions. Recently, these steps were also characterized in Pseudomonas aeruginosa17–
19.  
During the following year (2008), a series of studies20,21 revealing the mechanisms of 
CRISPR defence system were published and helped to establish the mechanism as well as 
function of CRISPR loci in adaptive immunity. Van der Oost and his team, through studying the 
type I CRISPR locus of Escherichia coli, was able to demonstrate that CRISPR arrays are transcribed 
and further processed into shorter crRNAs that contain distinct spacers with the function to guide 
Cas effector proteins such as Cascade20. In the same year, CRISPR-mediated defence from 
Staphylococcus epidermidis was demonstrated to block plasmid conjugation, proving that the 
target of Cas enzyme activity is DNA rather than RNA21. 
Having recognised CRISPR as a DNA-encoded, RNA-mediated and DNA-targeting immune 
system, a series of following studies investigated the biochemical and genetic processes 
supporting the mechanism of action22 . One critical discovery occurred also in 2008, consisting 
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on the existence and preservation of a CRISPR topic flanking the targeted phage sequences12,23,24, 
which was renamed the protospacer adjacent motif (PAM)12.  
Shortly after, in 2010, Moineau and colleagues used genetic studies in Streptococcus 
thermophilus to demonstrate that Cas9 (formerly called Cas5, Csn1, or Csx12) is an endonuclease 
that precisely creates double-stranded breaks in target DNA at specific positions, 3 nucleotides 
upstream from the 3ʹ edge of the protospacer sequence16. They also confirmed that Cas9 is the 
only protein required for cleavage in the CRISPR-Cas9 system 16. 
Subsequently in 2011, Emmanuelle Charpentier and colleagues performed small RNA 
sequencing on Streptococcus pyogenes (S. pyogenes) which has a CRISPR type II system and 
revealed that, in these types of systems, an auxiliary noncoding RNA, the trans-activating crRNA 
(tracrRNA) hybridizes with crRNA to create a dual RNA guide for Cas925. Still in 2011, Siksnys and 
colleagues set out to see whether the CRISPR system from S. thermophiles (Type II system) could 
be reconstituted, in a fully functional form, in an evolutionary distant bacteria, E. coli. So, they 
cloned the CRISPR-Cas locus from S. thermophiles and expressed it in E. coli, thus positively 
confirming that it can provide plasmid resistance26. 
In 2012 two huge milestones were reached, almost concurrently by two distinct groups, 
Emmanuelle Charpentier/Jennifer Doudna27 and Virginijus Siksnys28. Siksnys and his team proved 
that the Cas9–crRNA complex of the Streptococcus thermophilus CRISPR/Cas system introduces 
in vitro a double strand break in DNA that held a sequence that complemented the crRNA. They 
also proved that the DNA cleavage is performed by Cas9, using separate active sites (RuvC and 
HNH) to produce site specific nicks on opposite DNA strands28 and that the Cas9–crRNA complex 
acts as an RNA-guided endonuclease which uses RNA for the recognition of its target and protein 
(Cas9) mediated DNA cleavage. They also noted that the crRNA could be trimmed down to a 20-
nt (nucleotide) stretch, which is enough for efficient cleavage. Most remarkably, they 
demonstrated the possibility of reprogramming Cas9 by changing the sequence of the crRNA 
which consequently allows to target any desired site28. 
Furthermore, Emmanuelle Charpentier in collaboration with Jennifer Doudna reported 
similar findings as Siknys, but they also reported that the crRNA and the tracrRNA could be fused 
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together to engineer a single guide RNA (sgRNA). This sgRNA has two vital features including the 
20-nt sequence at the 5′ end of the sgRNA complementary to the DNA target site, and the double-
stranded structure at the 3′ side of the guide sequence that binds to Cas9, thus creating a system 
that by changing the guide sequence of the sgRNA can be used to engineer CRISPR-Cas9 to target 
any desired DNA sequence that is adjacent to a PAM27. 
In light of these studies, it became increasingly clear that there are several and diverse 
CRISPR–Cas systems in nature that share features (DNA-encoded, RNA-mediated, nucleic acid 
targeting), but also carry out peculiarities (various guide RNA types and structures, as well as 
cleavage outcomes), especially with regard to the type of nucleic acid targeted as some CRISPR–
Cas systems can actually target RNA29,30. 
Within months of the publishing of Emmanuelle Charpentier and Jennifer Doudna’s 
paper, a number of laboratories showed almost simultaneously that CRISPR–Cas9 molecular 
machineries can be repurposed to generate double-stranded breaks in DNA and lead to genome 
editing of mammalian cells using DNA repair systems31–33, giving rise to what has been termed 
the ‘CRISPR craze’34 and the transformation of genome editing35,36. Disruptive CRISPR-based 
technologies have since taken over, based on a number of Cas-based molecular technologies 
(Cas9, Cpf1, deactivated variants of Cas9) that enable genome editing, transcriptional control37–
39 and epigenetic alterations40. The many advantages and features of Cas proteins 
(programmability, transferability, affordability, specificity and efficiency, amongst many) have 
empowered geneticists throughout the world and the phylogenetic spectrum to change at will 
the genome and transcriptome of all genetically characterized species tested to date39. 
Current studies of CRISPR–Cas systems investigate the various aspects of the mechanism 
of action, with emphasis on novel immunity acquisition genetics and machinery41–44, as well as 
explaining the molecular and structural basis of interference by Cas nucleases45, and its 
evolutionary implications, particularly with regards to host/virus interactions19 and the impact of 
CRISPR immunity and targeting countermeasures17,46. 
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1.2 Genome Editing 
 
 Genome editing is a category of genetic manipulation that involves DNA being deleted, 
inserted or replaced in the genome of cellular organisms through engineered, programmable and 
highly specific nucleases such as meganucleases, Zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs) and CRISPR/Cas9, which can induce site-specific 
double-stand breaks (DSB) at the genomic locus to be modified47. 
Meganucleases or homing endonucleases (HEs) are modified forms of restriction enzymes 
that occur in nature that are characterized by having long DNA recognition sequences (12 to 40 
base pairs, (bp)). However, the downfall of meganucleases is the difficulty of manipulation due 
to the fact that these enzymes have their cleavage activity and DNA recognition tangled in only 
one domain48,49. 
TALENs and ZFNs are engineered restriction enzymes that are obtained by fusing a 
nonspecific DNA cleavage domain from the FokI endonuclease to a modified DNA binding 
domain. The repeat domains of TALEs and Zinc fingers that have tailored specificities can be 
combined into collections that bind to extended DNA sequences50.  
ZFNs are one of extensively used engineered nucleases that comprise a nuclease domain 
of the FokI restriction endonuclease and a Cys2–His2 DNA-binding domain50. However, it has 
been challenging to robustly produce engineered zinc finger arrays since it is required to consider 
how the distinct finger domains have context-dependent effects between them in an array51. 
 TALENs originated from a protein present in the bacteria Xanthomonas that is responsible 
for various diseases in plants. The DNA-binding domain of these restriction enzymes contain a 
conserved and repeated sequence of 33 to 35 amino acids, that individually recognize a specific 
nucleotide50. TALENs specificity to target DNA sequences can be modified by rearranging 
repeated amino acid recognition motifs. It appears that TALE repeat domains have less context-
dependent effects and can thus be produced to recognize almost any desired DNA sequence52, 
through the application of an easy code on a one-to-one basis between the distinct repeats and 
the four potential DNA nucleotides53. 
CRISPR: applications in human pathologies and future prospects 
 
 7 
More recently, CRISPR/Cas9 system offers another method for genome editing instead of 
the previously described meganucleases, ZFNs and TALENs. Contrary to the mechanisms of DNA 
cleavage of ZFNs and TALENs, the CRISPR/Cas9 system exploits small RNAs (crRNA, tracrRNA and 
sgRNA) for sequence-specific DNA cleavage in vitro47. The requirements of Cas9 to search for a 
DNA target are humble, demanding only a sequence of 20 nucleotides (nt) on the sgRNA that is 
able to base pair with the target DNA while simultaneously needing, adjacently to the 
complimentary region, the presence of a DNA protospacer adjacent motif (PAM).  
In Mammalian cells, nuclease-induced DSBs can be repaired by two pathways that function 
in almost every cellular organism. These are denominated homology-directed repair (HDR) and 
non-homologous end-joining (NHEJ) (Figure 1). The error-prone NHEJ-based modifications 
include small insertions or deletions (indels) that can interfere with the binding sites of factors 
that act in a trans-acting manner in enhancers or promoters and disturb the translational reading 
frame of a coding region. Thus, the NHEJ mechanism is mostly useful for gene inactivation and 
knock out. On the other hand, HDR-based modifications use a native (or engineered) DNA 
template to replace the targeted allele with a designed sequence by recombination. Additional 
DNA repair pathways such as single-strand annealing, alternative end joining, microhomology-
mediated joining, mismatch and base- and nucleotide-excision repair can also produce genome 
edits54,55. 
CRISPR: applications in human pathologies and future prospects 
 
 8 
 
As mentioned previously, nuclease-induced DSBs can be repaired by either NHEJ or HDR. 
In the absence of a repair template, DSBs are re-ligated through the NHEJ process, where indel 
mutations occur2. However, the HDR pathway can be favoured by using a repair template, which 
permits to edit precisely and with high fidelity56. Targeted DNA alterations require the use of 
traditional double-stranded plasmid-based donor DNA repair templates containing homology 
arms flanking the target site57 or, for small changes in a specific locus, the use of single-stranded 
DNA oligonucleotides (ssODNs)58. 
 The SURVEYOR nuclease assay59 or sequencing can be used to detect any indel mutations 
in cells that got co-transfected with sgRNAs to perform a genomic inversion or deletion2. HDR 
facilitated by both repair template deliveries can be checked through DNA amplification 
mediated by a polymerase chain reaction (PCR), followed by either a restriction-fragment length 
polymorphism (RFLP) analysis or by sequencing the altered site2. Both Sanger or deep sequencing 
can be used to detect the induced alterations in the genome2. 
Cas9 offers several potential advantages over ZFNs and TALENs. Cas9 is effortlessly 
customized as it can be easily retargeted to new DNA sequences by merely altering the 20-nt 
Figure 1- Mechanisms of double strand break repair. Nuclease-induced DSBs can be repaired by two pathways 
that function in almost every cellular organism, these are denominated homology-directed repair (HDR) and 
nonhomologous end joining (NHEJ). Repair facilitated by the NHEJ pathway is imprecise and can result in variable 
length indel mutations at the DSB location which, ultimately, can possibly lead to the formation of premature stop 
codons due to frameshifts. Repair facilitated by the HDR pathway is more precise and can result in the introduction 
of targeted insertions or point mutations from either ssDNA or dsDNA donor templates. NHEJ produces specific 
large deletions of DNA segments between two cut sites. Adapted from Maeder et al. 2016 (ref 65) 
 
CRISPR: applications in human pathologies and future prospects 
 
 9 
guide sequence2. On the other hand, retargeting of TALEN is a more exhausting effort as it entails 
making a couple of novel TALEN genes and even though several protocols for producing TALENs 
exist52,60–62, it is more time consuming to obtain two of these enzymes. Since it is recognised that 
S. pyogenes Cas9 (SpCas9) performs a blunt cut between bases at the 17th and 18th position in 
the sequence of interest27, it is possible to convert it into a DNA nicking enzyme by altering 
catalytic residues in the HNH or the RuvC nuclease domain of the enzyme27,63. Contrary to Cas9, 
TALENs have a non-specific DNA cleavage in the linker of 12–24 bp between the couple of TALEN 
monomer-binding sites64. Finally, while both SpCas9 and TALENs are known to mediate genome 
editing proficiently in a diversity of cell types and organisms65, Cas9 appears to be more efficient 
since it allows co-delivery of several sgRNAs into the target cells. This fact represents an 
advantage since this endonuclease can be used to edit numerous genomic loci concurrently. 
 
1.3 Structure and Mechanisms of CRISPR/Cas9 
 
Most archaea and numerous bacteria have acquired immunity against plasmid 
transmission and infections caused by viruses that affect these prokaryotes called 
bacteriophages. This immunity is achieved by a highly developed adaptive immune system that 
is guided by RNA sequences which are encoded in CRISPR loci and the associated Cas genes 
(Figure 2A). CRISPR loci contain short, repetitive and partially palindromic base sequences of 
around 30 to 40 bp that are separated by similarly small and unique spacer sequences (Figure 2) 
obtained upon infection from plasmids or bacteriophages. Therefore, spacer sequences are 
responsible for yielding a genetic record of previous infections which in turn allows the 
prokaryote to avoid future infections from identical invaders (Figure 2B) 41,66. 
Streptococcus pyogenes Cas9 is a large (1,368-amino-acid) multi-domain and 
multifunctional DNA endonuclease. It cuts double-strand DNA (dsDNA) 3 bp upstream of the PAM 
through its two different nuclease domains. The first one is an HNH-like nuclease domain that 
cleaves the DNA strand complementary to the guide RNA sequence, also known as the target 
strand, and an RuvC-like nuclease domain responsible for cleaving the DNA strand opposite to 
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the complementary strand, the nontarget strand27,28,67. Additionally, Cas9 also participates in 
crRNA maturation and spacer acquisition42. 
The immunity provided by the CRISPR array can be divided into two phases, as shown in 
Figure 2. Initially during the immunization phase (Figure 2A), a Cas complex identifies sequences 
from plasmids or viral genome and integrates a newly acquired repeat-spacer section at the 
leader end of the CRISPR array, resulting in the immunization of the prokaryote. Subsequently, if 
another infection attempt of the same invader occurs, the immune response is activated (Figure 
2B). During this stage of defence, the transcription of CRISPR sequence is set in motion resulting 
in a long pre-crRNA transcript that is processed into smaller and mature crRNAs that contains 
one spacer sequence at the 5’ end while the 3’ end contains a piece of CRISPR repeat sequence 
(Figure 2B). Afterwards, upon an infection of a familiar plasmid or bacteriophage, the mature 
crRNAs are used to guide the Cas endonucleases into recognizing and inactivating the foreign 
genetic material by cleaving plasmid or viral DNA (Figure 2B)13. 
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Figure 2-Crispr/Cas mechanism of action. A) Immunization phase: Upon insertion of foreign DNA into the affected 
prokaryote, the genetic material is recognised by the Cas complex and, subsequently, cleaved and integrated as a 
newly acquired spacer into the leader end of the CRISPR array; B) Immunity phase: Transcription of the CRISPR array 
occurs and pre-crRNA is obtained which is further processed into short and mature crRNA. These mature crRNAs are 
then used as guides for Cas RNA-guided nucleases that typically form a complex to interfere with the invading DNA. 
The Cas complex then identifies and cleaves the corresponding target sequence of the foreign nucleic acid, thus 
inactivating it. The spacers are represented as coloured rectangles, the repeat sequences as black rhombus and the 
CRISPR leader sequence as a white box labelled L.  Adapted from Horvath et al. 2010 (ref 1) 
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1.3.1 Mechanisms of different types of Crispr-Cas  
 
The cas1 and cas2 genes are present in all CRISPR/Cas systems and are known to be 
essential to the first phase of immunity provided by this defence mechanism. However, three 
distinct system types exist that can be distinguished based on the presence of accessory cas 
genes68. Despite the fact that the three types of CRISPR/Cas systems use the same method of 
DNA cleavage through crRNA-guided nucleases, they diverge in targeting requirements and the 
generation of crRNAs68.  
The immunity provided by the type I CRISPR/Cas system is carried out by the Cas3 
nuclease in combination with the Cascade complex (Figure 3A)20. After the pre-crRNA is produced 
by transcribing the CRISPR sequence, a Cascade subunit denominated Cas6e with 
endoribonuclease activity is responsible for the cleavage into small and mature crRNAs that stay 
linked to the complex and are, subsequently, employed by Cascade to find the target protospacer 
sequence20. Situated right upstream of the target sequence is a small sequence motif that is 
recognized by an additional subunit known as Cas869.  
For the immunity mediated by the type I CRISPR/Cas system to occur, it is compulsory to 
recognize a PAM sequence. For this reason, an autoimmune response is avoided with the absence 
of a PAM sequence in the repeat sequences since crRNA is thus unable to target the spacers of 
the CRISPR sequence. When a matching sequence is flanked by a PAM, the Cascade complex is 
able to bind to the target DNA which results in an R-loop between the dsDNA and the crRNA. 
Finally, the target recognition by Cascade recruits and engages Cas3 that is responsible for 
introducing single-stranded DNA (ssDNA) breaks into the target plasmid or viral DNA70, 
consequently inactivating them71. 
The immunity by the type II CRISPR/Cas system is achieved by using only a single cas gene 
called cas9 in combination with a crRNA guide for target recognition (Figure 3B). In contrast with 
the other types, the type II CRISPR/Cas system requires an additional short RNA known as the 
trans-activating crRNA (tracrRNA). This RNA is partially complementary to crRNA as it has an area 
that shares complementarity with the repeat sequences of CRISPR and additionally it establishes 
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a secondary structure facilitating its aggregation with the enzyme Cas9. The pre-crRNA is further 
processed into short crRNA guides by the cleavage mediated by ribonuclease (RNase) III that 
cleaves the double-strand RNA (dsRNA) formed between the pre-crRNA and the tracrRNA25. 
Similarly, immunity mediated by the type II CRISPR/Cas system can only occur in the 
presence of a PAM sequence. This sequence is recognised by Cas9 through a PAM-binding 
domain but, differently from type I, in this immunity the PAM is located directly downstream of 
the sequence that is targeted. Cas9 has two nuclease domains known as HNH and RuvC that are 
responsible for the specific dsDNA breaks in both the DNA strands of the foreign DNA that is 
facilitated by the type II CRISPR/Cas system71. The target recognition is initiated by Cas9 
transiently binding to PAM sequences of the foreign DNA, enabling the denaturation of the two 
DNA strands that are directly upstream of the PAM sequence. Targeted cleavage occurs after an 
R-loop forms due to a productive interaction of the denatured DNA with the crRNA guide in the 
aforementioned target area71. 
In the immunity provided by the type III CRISPR/Cas system, a repeat-specific 
endoribonuclease that does not belong to a complex, called Cas6, is responsible for cleaving the 
pre-crRNA (Figure 3C). A sequence at the 5’ end of the spacer denominated crRNA tag contains 
8 nucleotides remaining from the repeat sequence due to the CRISPR/Cas type processing 72. 
Afterwards, the short crRNAs produced through the cleavage mediated by Cas6 are relocated, by 
an unidentified mechanism, to a Cas10–Csm complex in case of a type III-A system or to Cas10–
Cmr complex in case of a type III-B system73. These complexes are responsible for trimming the 
3’ end of the crRNAs at intervals of 6 nucleotides, resulting in a mature crRNAs74. While the other 
system types depended solely on recognizing DNA sequences, the immunity provided by the type 
III CRISPR/Cas system additionally necessitates the transcription of the target sequence and 
complementarity to the transcript and the target non-template DNA strand by the crRNA for 
cleavage to occur75. Therefore, type III Crispr/Cas is able to target both the foreign DNA and its 
transcript, leading to the crRNA-guided cleavage by the Cas10 complex76. The cleavage of the 
non-template strand occurs in the palm domain of Cas10, while the cleavage of the RNA 
transcripts for the type III-A is mediated by the backbone subunit Csm3 and for the type III-B 
system by the backbone subunit Cmr476. 
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Figure 3- Mechanisms of different Crispr/Cas types. A) Type I systems possess a Cas protein complex (Cascade) that 
is responsible for cleaving each repeat at the base of the stem–loop structure in the pre-crRNA, which results in the 
formation of short crRNA guides. Subsequently, the Cascade in combination with crRNA examines the target DNA to 
find a protospacer that is flanked by a PAM sequence. Finally, the crRNA anneals to the target strand forming an R-
loop and, afterwards. the Cas3 nuclease is recruited and activated into cleaving the target sequence downstream of 
the PAM, resulting in the destruction of the opposite strand; B) Type II system encode a small tracrRNA that is 
aggregated to Cas9 and is partially complementary to repeat sequences of CRISPR. RNase III is responsible for 
cleaving the repeat/tracrRNA to obtain crRNA guides for the Cas9 nuclease. This enzyme after recognizing a target 
sequence, mediates the cleavage of both strands of the protospacer/crRNA R-loop; C) Type III systems encode a 
repeat-specific endoribonuclease that does not belong to a complex called Cas6, which is responsible for cleaving 
the pre-crRNA into crRNA that is subsequently relocated into the Cas10 complex where it is cleaved to produce a 
mature crRNA. The complex additionally necessitates transcription of the target sequence and complementarity to 
the transcript and the target DNA non-template strand by the crRNA for cleavage of both sequences to take place. 
Adapted from Marrafini et al. 2015 (ref 22) 
 
The type III CRISPR/Cas system depends on the disparity in base pairing of the crRNA and 
the sequences that are adjacent to the protospacer to avoid targeting the CRISPR array72. 
Therefore, no autoimmunity is caused by this system because the DNA targeting is prevented 
when the crRNA tag is totally complementary to the DNA repeats within the CRISPR locus. 
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Contrarily, DNA targeting is permitted in case of incomplete complementarity between the 
sequences flanking the protospacer and the crRNA tag72. 
 
1.4 Delivery Methods of CRISPR/Cas9 
 
The sgRNAs and Cas9 can be delivered by different methods depending on the application 
including DNA constructs, mRNA constructs or Cas9 ribonucleoproteins77. While both crRNA and 
tracrRNA can be delivered separately, the combination into a single chimeric gRNA simplifies 
both design and delivery. The gRNA can either be expressed from a plasmid inside the cell or 
generated via in vitro transcription77. One way of delivery is through PCR amplicons containing 
an expression cassette2. PCR-based sgRNA delivery attaches the custom sgRNA sequence onto 
the reverse PCR primer used to amplify a U6 promoter template and the resulting amplicon could 
be co-transfected with a Cas9 expression plasmid. Since this method removes the need for 
plasmid-based cloning and sequence verification, it is suitable for testing or co-transfecting 
numerous sgRNAs for generating large knockout libraries or other scale-sensitive applications2. 
Early efforts in mammalian cells focused on encoding Cas9 in the form of DNA 
plasmids63,78. In this method, a single plasmid can be used to encode both the chimeric gRNA and 
the Cas9 under separate promoters. Typically, the Cas9 is encoded as a fusion to a nuclear 
localization signal that mediates intranuclear transduction upon expression, thus allowing access 
to the genetic material of the cell63,78,79. The delivery of the plasmid DNA into the cells is attained 
either via standard chemical transfection or electroporation methods77. 
A more complex delivery method is packaging the Cas9 DNA in a single-stranded form 
within a non-integrating virus such as adeno-associated virus (AAV)80.  However, the maximum 
packaging capacity for AAV is approximately 4.5 kb81, which makes combination of both the Cas9 
and cognate gRNA into a single capsid challenging. As such, smaller Cas9 variants82 and several 
systems to create split Cas9 enzymes83–85, allowing division between two AAV vectors, have been 
developed but both suffer from reduced efficacy82–85. Another path for AAV-based delivery lies 
in the use of significantly smaller Cas9 orthologs from other species as reported by Ran et al.86. 
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Cas9 isolated from S. aureus can edit mammalian genomes with similar efficiencies to S. Pyogenes 
Cas9 while being more than 1 kb shorter when encoded in DNA form, allowing packaging within 
a single AAV capsid86. 
Another way of reducing the size of Cas9 delivered to cells is to generate RNA transcripts 
of the gene. Cas9 mRNA delivery has been extensively adopted for the ex vivo modification of 
mammalian embryos by microinjection87–89, and more recently in human somatic cell lines90, or 
primary cells91 via electroporation. RNA constructs can also be delivered in viral form, usually in 
the form of integrase defective lentiviral particles. The lentivirus capsid has a substantially larger 
capacity for nucleic acid (approximately 8 kb)92 compared to AAV, and so it can be engineered to 
express both Cas9 and up to four gRNAs simultaneously93,94. 
A more recent line of investigation has been to deliver ribonucleoproteins (RNPs), which 
are composed of Cas9 protein precomplexed with gRNA90,95,96. Delivering Cas9 in protein form 
leads to fewer observed off-target mutations than delivery via plasmid DNA90,95,96. Non-standard 
techniques for the delivery of Cas9 RNPs are also being explored. These include lipid-based 
transfection reagents97, nanoparticle carriers of Cas998 and non-lipid carriers that mimic vesicle-
like structures99. 
The range of delivery options for Cas9 RNPs is further expanded upon modification of the 
Cas9 protein termini to allow for covalent functionalization such as conjugation to cell 
penetrating peptides (CPPs)100,101. 
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2. APPLICATIONS 
 
Engineered nucleases have quickly become a frequently used method by researchers for 
targeted genome editing, especially because of the recent arrival of CRISPR with the combination 
of the highly customizable Cas9102. 
Genome editing with these engineered nucleases has been used in a quick, easy and 
efficient manner to modify endogenous genes in a diverse set of biomedical relevant cell types 
and in organisms that have previously been difficult to modify genetically 32. It has quickly 
overcome TALENs103 and ZFNs104 where editing was excessively complex and arduous. 
In the research arena, versatile CRISPR-enabled genome editing has been used in various 
fields, such as medicine65, biotechnology105 and biology106 with diverse applications such as: 
controlling transcription, modifying epigenomes, conducting genome-wide screens, imaging 
chromosomes, manipulating biological circuits facilitating the generation of synthetic materials, 
correcting gene mutations, control the expression of entire genes offering longer term expression 
alteration compared to other methods such as RNAi102,107. CRISPR systems are already being used 
to improve genetic disorders in animals and are likely to be employed soon to treat human 
diseases of the eye and blood108. Beyond biomedical applications, this system is already being 
used to expedite crop109,110 and livestock breeding111, develop new antimicrobials112 and control 
insects that carry diseases with gene drives113. The CRISPR technology is already providing a new 
class of genetic models that are more suited for diverse applications such as rapid diagnostics, 
fundamental disease research, drug screening and therapy development, in vivo editing and 
correction of inherited conditions114. 
Even though the genome-wide specificities of the CRISPR/Cas9 technology remain to be 
fully understood, the ability of these systems to execute targeted alterations of genome 
sequences and gene expressions with high efficiency will unquestionably alter biological research 
and encourage the development of new molecular therapeutics for diseases affecting 
mankind.114 
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The applications of the CRISPR/Cas9 system in human pathologies will be further explored 
in the following chapters. 
 
2.1 Antiviral Therapy 
 
Antiviral therapy through designer nuclease CRISPR/Cas9 has become a promising new tool 
against human infecting viruses. This method has been used successfully to target viral genes or 
host genes that encode vital receptors to inhibit infection and replication of viruses115. 
 
2.1.1 HIV 
 
The human immunodeficiency virus (HIV) is a member of the genus Lentivirus, part of the 
family Retroviridae116 that causes a viral infection and progresses to an acquired 
immunodeficiency syndrome (AIDS). AIDS is responsible for a progressive deterioration of the 
human immune system, allowing lethal opportunistic infections and cancers to flourish117. 
Transmission of HIV occurs by blood transfer, pre-ejaculate, semen, vaginal fluids, and from 
mother to child during pregnancy, delivery or breastfeeding118.  
HIV infects essentially the human immune system cells including the vital helper T cells 
(CD4+ T cells) (Figure 4), dendritic cells and macrophages. The infection, consequently, leads to 
low levels of helper T cells through numerous mechanisms, including apoptosis of uninfected 
bystander cells, pyroptosis of abortively infected T cells, direct viral killing of infected cells, and 
by CD8 cytotoxic lymphocytes killing the infected cells. Cell-mediated immunity can be lost if 
helper T cell numbers drop below a set level, which leads to increasing susceptibility to 
opportunistic infections119. 
CRISPR: applications in human pathologies and future prospects 
 
 19 
 
 
 
Therapeutic interventions mainly target two key retroviral enzymes: reverse transcriptase 
and protease. In combination, these antiviral drugs have greatly diminished both mortality and 
morbidity in HIV infected patients. However, when administered over prolonged periods, these 
drugs induce considerable toxicity, and their effectiveness is undermined by the emergence of 
drug-resistant strains of HIV120. 
Although current anti-HIV therapies can inhibit HIV-1 replication, the viruses that have 
integrated within the host genome in a latent state can still potentially reactivate at any time. 
Figure 4- HIV replication cycle. The main steps in HIV replication are sequentially numbered from 1 to 6. (1) Virus 
binds to CD4 and the appropriate coreceptor resulting in fusion of the viral envelope and the cellular membrane, 
leading to the viral nucleocapsid being released into the cytoplasm. (2) The viral RNA is uncoated. (3) subsequently, 
reverse transcription mediated by the Reverse Transcriptase (RT) occurs. (4) The obtained viral dsDNA then migrates 
into nucleus of the affected CD4+ cell and is posteriorly integrated into the cellular DNA by the enzyme Integrase. (5) 
Afterwards, transcription of the proviral DNA mediated by the cellular RNA polymerase II occurs producing mRNAs. 
Then, translation of these RNA molecules is facilitated by the cellular polyribosomes. (6) Genomic RNA and proteins 
of viral origin are transported to the cellular membrane, where assembly occurs. Immature virions are released. The 
viral protease is then responsible for processing the polypeptide precursors to generate mature viral particles. After 
migrating to the cell’s plasma membrane, the virus particles suffer a budding process, resulting in the release of the 
new HIV particle. Adapted from Fanales-Belasio et al. 2010 (ref 122) 
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The CRISPR/Cas9 system has proved to be useful for eliminating latent HIV-1 by targeting its 
genomic DNA. Several groups have reported that they successfully disrupted the expression of 
HIV-1 provirus in infected cells utilizing the CRISPR/Cas9 system121–124. More recently a team 
successfully excised the HIV-1 provirus in three different animal models using an all-in-one 
adeno-associated virus vector to deliver multiplex sgRNAs and Staphylococcus aureus Cas9 
(saCas9)108. The published results demonstrate the plausibility of engineering Cas9/gRNA to 
precise and efficiently obtain a prophylactic and therapeutic method against AIDS. 
 
2.1.2 Epstein-Barr Virus 
 
Epstein-Barr virus (EBV) or human herpesvirus 4, belongs to the herpes virus family and 
is one of the most common human viruses125. The virus usually spreads through bodily fluids, 
mostly saliva125. EBV can cause several health issues such as infectious mononucleosis, some 
forms of cancer and can also affect the nervous and autoimmune systems125. 
Most infections occur during infancy and early childhood and present either no symptoms 
or nonspecific symptoms. However, in adolescents and young adults, EBV infection commonly 
results in infectious mononucleosis with symptoms including fever, sore throat, 
lymphadenopathy and splenomegaly. Additionally, other symptoms and signs may be present 
such as headache, fatigue, rash and hepatomegaly125. 
EBV infects B cells of the immune system and epithelial cells. After controlling the initial 
lytic infection, EBV persists latently in B cells for the rest of the affected person’s life.  In some 
cases, the virus may reactivate in asymptomatic form and people with weakened immune 
systems can even develop symptoms. If EBV reactivates it can infect others125. 
Currently there is no treatment for Epstein-Barr Virus, however some measures can be 
taken to help relieve the symptoms including fluid intake, resting and using medication for pain 
and fever125.  
In 2014, Wang et al.126 reported to have successfully applied CRISPR/Cas9 as an antiviral 
treatment in human cells by specifically targeting the genomes of latent Epstein-Barr virus. There 
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was a halt in proliferation and an associated reduction in viral load in cells from a Burkitt’s 
lymphoma with latent EBV after being exposed to the CRISPR/Cas9 system that targeted the viral 
genome. 
In 2015 Yuen et al.127 used two gRNAs to introduce a 558bp deletion in the promoter 
region of BamHI-A rightward transcript (BART) which encodes viral microRNAs (miRNAs) on the 
EBV genome. Numerous latently infected human epithelial cell lines such as nasopharyngeal 
carcinoma C666-1128 cells were successfully edited. They observed efficient editing of the EBV 
genome by the CRISPR/cas9 system as the whole pBART region was eliminated which resulted in 
the loss of miR-BART expression and activity. Their results represented the first genetic evidence 
that the major promoter for the expression of BART is pBART. Finally, after cells expressing Cas9 
and gRNAs were selected with puromycin, a recombinant virus with the intended deletion was 
obtained and deep sequencing revealed no off-target cleavage127.  
Van Diemen and his team129 showed that the CRISPR/Cas9 system is able to directly edit 
the genome of latent EBV in EBV-positive tumor cells and that targeting vital areas of the virus 
dsDNA efficiently reduces the content of viral genome in latently infected cells. They designed 
gRNAs aiming for the viral EBV nuclear antigen 1 (EBNA1) and numerous parts of the origin of 
replication (OriP) of the Epstein-Barr virus that are involved in its replication and episome 
maintenance130,131. 
Their team used Burkitt’s lymphoma Akata-Bx1 cells as model system. These cells carry a 
recombinant EBV expressing green fluorescence protein (eGFP) under control of the 
cytomegalovirus (CMV) promoter132. Therefore, the expression of the eGFP is a signal of EBV 
presence in these cells129. After the transduction of the cells with their corresponding gRNAs, a 
loss of eGFP expression was observed. A near full loss of eGFP from most of the cells was 
observed after introducing a combination of these active gRNAs. Finally, they showed that the 
most efficient method was targeting EBNA1 with two different gRNAs, which induced over 95% 
loss of EBV genomes129. 
The results obtained by Van Diemen’s team demonstrate that viral genome content in 
latently EBV infected cells can by efficiently reduced by the CRISPR/Cas9 system when it is 
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targeted at vital areas of the EBV dsDNA and that this reduction could culminate on a termination 
of the tumorigenic, cell cycle-promoting roles carried out by EBV and the loss of anti-
inflammatory functions and counter-apoptotic features of gene products encoded by the virus. 
Therefore, this approach might be a new therapeutic strategy to fight malignancies associated 
with the Epstein-Barr virus129. 
In early 2017, Ma and colleagues133 used the CRISPR/Cas9 system to perform genome-
wide loss-of-function screens to identify host dependency factors that are critical for the EBV 
infected lymphoblastoid and Burkitt lymphoma B cell growth and survival. They managed to 
identify multiple non-redundant mechanisms by which EBV prevents apoptotic responses to 
oncogene stress in transformed B cells and identified key EBV-induced synthetic lethal targets for 
therapeutic intervention. 
Yuen et al.134 reported suppression of EBV in latently infected nasopharyngeal carcinoma 
cells when using the CRISPR/Cas9 system. They studied the possibility of the CRISPR/Cas9 system 
to induce a reduction of EBV levels by targeting the genome of the virus in infected 
nasopharyngeal carcinoma cells. They engineered several gRNAs aimed towards different areas 
of the viral genome and transfected them into C666-1 cells128. The team observed a reduction by 
half of the viral DNA levels in C666-1 cells and even though this effect lasted for weeks134. Lastly, 
they observed that the survival of C666-1 cells did not change. However, these cells became 
sensitized to the chemotherapeutic effect of 5-fluorouracil and cisplatin134. The authors consider 
that this work provides the proof-of-concept for suppressing EBV DNA load with CRISPR/Cas9 and 
that it may lead to a potential new strategy to sensitize EBV infected nasopharyngeal carcinoma 
cells to chemotherapy which in turn might reduce the necessary dose of these drugs, thereby 
alleviating the side effects. However, the team has concerns about possible off-target effects and 
the adequate delivery vehicle. All these issues need to be addressed before CRISPR/Cas9 
technology can enter the next phase of medical applications134. 
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2.1.3 Hepatitis B virus 
 
Hepatitis B is a viral infection affecting the liver caused by the Hepatitis B virus (HBV)135. 
The virus is transmitted from person to person through contact with the infected blood, semen 
or other infected body fluids136. Normally, it is an acute infection with a short duration, but it can 
also become a lasting, chronic infection. The risk of developing a chronic infection is associated 
with the age of the infected person. Most (90%) infected infants become chronically infected, 
while only a small fraction of infected adults (2% to 6%) become chronically ill135. It is best to 
prevent Hepatitis B infection by getting vaccinated as the chronic illness can lead to severe health 
problems, including hepatocellular carcinoma or cirrhosis136. 
It may take approximately 90 days for symptoms to appear. The initial infection may 
present no symptoms in some people, while others may develop a rapid onset of sickness. The 
symptoms commonly last some weeks and this initial stage of the disease rarely results in death 
of the infected person135. The presence of symptoms differs depending on the age. Most children 
under age 5 and newly infected immunosuppressed adults are asymptomatic, whereas 30% to 
50% of persons over 5 years old have initial symptoms136. The symptoms are mainly non-specific 
and can include: Fatigue, fever, nausea, loss of appetite, vomiting, abdominal pain, joint pain, 
jaundice, dark urine and clay-coloured bowel movements135. 
Since 1982, there has been an effective vaccine against hepatitis B. The vaccine is 95% 
effective in preventing early viral infection and the progress into chronic illness and liver 
cancer136. There is no specific treatment for acute hepatitis B and the only therapeutic option 
available is to treat the patient’s symptoms relieving their discomfort. For example, lost fluids 
from diarrhea and vomiting are replenished to guarantee appropriate nutritional balance136. On 
the other hand, chronic hepatitis B infection can be treated with antiviral medication. The 
treatment can slow down the development of cirrhosis, decrease occurrence of liver cancer and 
ultimately improve long-term survival of those affected by the virus. However, the 
abovementioned antiviral therapy only suppresses the viral replication and therefore does not 
provide a cure for hepatitis B136. 
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Several in vitro and in vivo studies demonstrated that using the CRISPR/Cas9 system to 
target the HBV cccDNA is successful and efficiently inhibits HBV replication137–142. Seeger et al.137 
showed that their team could inhibit HBV infections up to eightfold by testing several HBV-
specific gRNAs. They demonstrated that Cas9 could certainly cleave the virus-derived cccDNA and 
that the resulting cleaved cccDNA is swiftly repaired, possibly by the NHEJ pathway. Even though 
the authors of this study did not show the experimental feasibility, they consider that this method 
can be applied to future investigations that study the role of host genes in the viral life cycle by 
inactivating relevant cellular genes. 
Lin et al.138 designed eight sgRNAs that target the P1 and XCp genes on HBV. In this study, 
they found a significant reduction in the production of core and HBsAg proteins in Huh-7 
hepatocytes derived from cellular carcinoma cells. In a mouse model, it was shown that this 
method could cleave the intrahepatic plasmid that contained the viral genome and enable its 
clearance, which resulted in a decrease of serum surface antigen levels138.  
Furthermore, Zhen et al.139 used CRISPR-Cas9 to target the Hepatitis B antigen (HBsAg) on 
HBV in vitro culture and within in vivo systems that were confirmed by quantitative enzyme-
linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (qPCR). The 
total amount of HBsAg secreted into the cell culture and in the mouse serum was reduced after 
editing the gene with CRISPR-Cas9. In the same study, they also found that no HBsAg-positive 
cells persisted in the liver tissue of CRISPR-Cas9 treated mice, and this was confirmed by 
immunohistochemistry139.  
CRISPR/Cas9 system has also been used by Dong and colleagues140 to target the HBV 
cccDNA, which is highly stable, and a prime target for the inhibition of HBV infection. This work 
showed a reduction in the generation of the virus in Huh7 cells and in HepG2.2.15 HBV-
replication cells140. Similarly, Kennedy et al.141 used Cas9 and HBV-specific sgRNAs. The total viral 
DNA load was reduced by up to 1000-fold and cccDNA was reduced by up to 10-fold, and 
outstandingly remaining viral DNA was mutated141.  
CRISPR: applications in human pathologies and future prospects 
 
 25 
These studies can be further expanded and explored with the hope of developing a novel 
therapeutic strategy, not only against chronic HBV infection, but also against the wider family of 
other hepatitis viruses in the future. 
 
2.1.4 Human papillomavirus 
 
Human papillomavirus (HPV) is a DNA virus belonging to the papillomavirus family and 
can cause infection in humans affecting the skin and the moist membranes lining of the body 
(cervix, anus, mouth and throat)143,144.  
HPV is the most common sexually transmitted infection (STI) worldwide and there are 
more than 170 types of HPV, of these at least 13 are known to cause cancer143,144. The virus is 
primarily transmitted by sexual interaction and, generally, people are infected with it soon after 
the beginning of sexual activity144. Most HPV infections do not cause symptoms but some HPV 
types (primarily types 6 and 11) can cause warts143. A small proportion of infections with some 
types of HPV can persist and progress to various types of cancer such as: cervical cancer 
(approximately 70% of cervical cancer cases can be attributable to HPV infection), cancers of the 
anus, vulva, vagina, and penis144. 
Moreover, persistent infection with specific types of HPV, most frequently types 16 
and 18, have the highest risk for development of genital cancers143. Symptoms of cervical 
cancer normally only appear after it has gotten to a more advanced stage and may include 
non-specific symptoms: loss of appetite and weight loss; fatigue; leg, back or pelvic pain; a 
single swollen leg; vaginal odorous discharge or discomfort; and irregular, abnormal or 
intermenstrual vaginal bleeding after sexual intercourse143. 
There are currently 3 vaccines that protect against some cancer causing HPV types: 
Cervarix® protects against HPV types 16 and 18145, Gardasil® protects against HPV types 6, 11, 
16, 18146 and Gardasil 9® which in addition to protecting against infection by strains covered 
by the previous generation of Gardasil, also protects against five other HPV strains (31, 33, 45, 
52, 58) that are the cause for one fifth of cervical cancers147. 
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There is medical interest in the high-risk HPV E6 and E7 proteins because of their 
associated tumor suppressor p53 and retinoblastoma (Rb) interference that can result in the 
formation of tumors. The E6 protein promotes cell proliferation through stimulating the 
degradation of the tumor suppressor p53 protein by the formation of a trimeric complex 
containing E6, p53 and the cellular ubiquitination enzyme E6-AP. E6 degradation interferes with 
the biological functions of p53 disturbing the control of the cell cycle progression and resulting 
in increased tumor cell growth148. 
E7 binds to a region of the Rb protein that is essential for its tumor suppressor function. 
One of the major biochemical functions of Rb as a tumor suppressor is to bind E2F-family of 
transcription factors and repressing the expression of replication enzyme genes149. E7 disrupts 
the interaction between Rb and E2F, resulting in the release of E2F factors in their 
transcriptionally active forms, thus stimulating replication and cell division150. 
Kennedy et al.151 have successfully used CRISPR-Cas9 machinery to disable the viral genes 
E6 and E7 in both HPV18 and HPV16, using HeLa and SiHa cervical carcinoma cell lines. They 
reported that the expression of Cas9 RNA-guided endonuclease, together with sgRNAs specific 
for E6 or E7 cleave the HPV genome, resulting in gene inactivating indel mutations. This induces 
p53 and Rb expression that are able to stall the cell cycle and initiate apoptosis.  
Recently, Liu et al.152 reported that a CRISPR-Cas9 system using a dual guide RNA vector 
successfully targeted and deactivated the E7 gene in HPV types 6 and 11 in keratinocytes. The 
results showed that silencing of E7 led to inhibition of cell proliferation and induction of apoptosis 
in E7-transformed keratinocytes. The data showed potential for the development of an adjuvant 
therapy for genital warts. 
 
2.1.5 John Cunningham Virus 
 
Lytic infection of oligodendrocytes by John Cunningham Virus (JCV) in the central nervous 
system (CNS) is the cause of the fatal demyelinating disease, progressive multifocal 
encephalopathy (PML)153. This disease mostly develops in people who have underlying 
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immunosuppressive conditions, such as AIDS154,155, Hodgkin’s lymphoma156, lymphoproliferative 
diseases157, and in those undergoing antineoplastic therapy158,159. Similarly, this disease seems to 
be steadily increasing amid patients with autoimmune diseases, such as Crohn’s disease160 and 
multiple sclerosis161–163, who are treated with antibody therapies. 
PML is a sub-cortical white matter disease of the brain and exhibits signs and symptoms 
suggestive of the involvement of multiple regions of the brain164–166. While demyelination can 
develop in any location in the white matter, it can also occur in other regions of the CNS164–166. 
The most common symptom of PML is visual deficit, accounting for 35 to 45% of the cases. 
Mental deficits, another devastating sign of PML, and motor weakness is also observed in a 
considerable number of patients accounting for a third and 25 to 33% of all cases, respectively164. 
The disease can progress quickly, causing death within four to six months, although clinical signs 
and symptoms may persist stable for a longer period164,165,167. 
Currently, there is no effective treatment for PML168 even though several therapeutic 
approaches such as heparin sulfate, cytarabine and interferons have been used to treat this 
illness153. Therefore, the development of novel effective therapies for PML is urgently needed. In 
this regard, two studies involving the use of the CRISPR/cas9 system as a therapeutic strategy 
targeting the JCV have been reported169,170. 
T-antigen (T-ag) is a viral early protein that is essential for directing viral reactivation and 
lytic infection, which is encoded in the small circular double stranded DNA of the JCV genome171. 
Wolebo et al.169 employed in vitro, the CRISPR/cas9 system to introduce mutations in the viral 
genome and, by inactivating the gene encoding T-ag, they inhibited viral replication. This method 
could potentially be used to eliminate both actively replicating virus in patients with PML and 
asymptomatic persistent virus in persons without the disease but that are prone to develop it. 
In the work reported by Wolebo and colleagues169, it is probable that before the initiation 
of DNA replication, the viral genome was already targeted since gRNAs and the CRISPR/Cas9 
system were already inside the cells before introducing the aforementioned viral genome. To 
further assess this, Chou et al.170 studied the possibility of effectively restricting viral replication 
with the CRISPR/Cas9 system in cells that were already acutely infected prior to the introduction 
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of CRISPR/Cas9. It was observed that the replication of the JCV was greatly impaired when the 
host cell unsuccessfully repaired the DNA cleavage by CRISPR/Cas9 in susceptible regions of the 
JCV genome. In addition to Wolebo’s team findings169, these results confirm that CRISPR/Cas9 in 
conjunction with the appropriate gRNAs targeting the JCV genome can indeed hinder viral 
replication and thus the infection when introduced into cells that were already acutely infected 
prior to this insertion170. 
The results described above suggest that the CRISPR/Cas9 system could be of valuable 
interest in the quest of finding an effective therapy against the deadly PML. However, both teams 
admit that development and optimisation of an efficient delivery vehicle is needed before further 
clinical consideration169,170. 
 
2.1.6 Herpes simplex virus 
 
Infection with herpes simplex virus currently results in a lifetime infection and can be due 
to either herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2). Generally, 
HSV-1 is associated with orolabial disease, whereas HSV-2 is almost entirely associated with 
genital disease172. However, genital herpes caused by HSV-1 has been reported173–176. Globally, 
an estimated 3.7 billion people under the age of 50 (67%) and 417 million people aged 15-49 
(11%) have HSV-1 or HSV-2 infections, respectively177. 
Although both genital and oral herpes infections are usually asymptomatic, some 
symptoms can still occur. In oral HSV-1 infections symptoms include painful blisters or open sores 
in or around the mouth and before the presence of these ulcers there might be a sensation of 
burning, itching or tingling in the affected area. Similarly, anal or genital ulcers or blisters can 
occur in people with genital herpes. Newly acquired genital herpes infections can present 
additional symptoms such as swollen lymph nodes, fever and body aches. When the cause of 
infection is HSV-2, preceding the appearance of genital ulcers there might be feelings of localized 
pain or mild tingling172,177. Possible complications may occur including severe disease, neonatal 
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herpes and psychosocial impact. Additionally, HSV-2 and HIV influence each other by improving 
the transmission rate and severity of disease172,177. 
Currently, there is a limited amount of options for treating the symptomatology of a 
herpes infection and all the existing antiviral agents that are approved have the viral DNA 
polymerase as a common target during the lytic phase of infection178. However, herpesvirus also 
possess the ability to evade the human immune system by establishing a latent state in which 
the virus expresses limited gene products179. Furthermore, viral DNA polymerases do not actively 
replicate the herpesvirus genome during this state which ultimately leads to ineffective antiviral 
therapies that target this enzyme178. 
Van Diemen et al.129 designed an in vitro study to determine if the CRISPR/Cas9 system 
can be reprogrammed to effectively hinder an infection by herpes simplex during both productive 
and quiescent stages of its life cycle. With this approach, they intended to achieve successful 
editing of the HSV-1 genome, which consequently, would lead to reduced virus replication by 
directing gRNAs to essential viral genes. However, the research team observed that when they 
used only one gRNA targeting the herpesvirus genome, a selection of mutants resistant to the 
CRISPR/Cas9 editing arose when there was a continued proliferation of infected cells. The team 
then envisioned that they could more successfully hinder viral replication by concurrently 
targeting several vital viral genes and consequently avoid the formation of mutants. They tested 
this idea by using two gRNAs to target the HSV-1 genome and they successfully achieved a halt 
in the replication of the virus in human cells. 
Van Diemen and colleagues129 also assessed whether the CRISPR/Cas9 system could 
target the latent state of HSV-1 in infected cells but, in contrary to the results obtained in the 
productive stage, CRISPR/Cas9 seemed to be ineffective at targeting latent HSV-1 genomes but 
the viral replication could again be successfully stopped upon virus reactivation. The authors 
consider that CRISPR/Cas9 system may be inefficient in accessing the tightly repressed state180 
of the HSV-1 quiescent genome. However, further in vivo and in vitro studies are necessary to 
clarify if the CRISPR/Cas9 system can target latent state HSV-1. 
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The study presented above indicates the potential of the CRISPR/Cas9 system as an 
attractive new strategy to combat pathogenic human herpesvirus by directly hindering viral 
replication and thus eliminating this pathogen from infected cells and, upon optimization, could 
also be used to target latent HSV-1. 
 
2.2 Genetic disorders 
 
A genetic disorder is a condition caused by an abnormality or mutation in an individual's 
DNA sequence. Mutations can be caused by an error in DNA replication, environmental factors 
or can also be hereditary181. 
Genetic disorders can be categorized in three different groups, monogenic disorders, 
chromosome disorders and multifactorial disorders181. Monogenic disorders are caused by a 
mutation in a single gene and can be dominant or recessive181. Autosomal dominant disorder 
means that only one mutated copy of the gene is necessary to develop the disease, the chance 
of a child inheriting this type of disorder is of 50%181. Autosomal recessive disorder requires the 
presence of two copies of the mutated gene for a person to be affected by the disease, the chance 
of inheriting this type of disorder is of 25%181. If the mutated allele is in the X chromosome, a 
disorder can be recessive in women but dominant in man and the inheritance can be different if 
the child is male or female. Chromosome disorders result from alterations in the number or 
structure of the genes that are in the chromosomes181. Multifactorial disorders are caused by a 
combination of multiple gene mutations associated to environmental and lifestyle factors181. 
Recently, CRISPR/Cas9 has been used as a novel editing tool for the development of new 
treatments of genetic disorders, which will be further discussed below. 
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2.2.1 β-thalassemia  
 
β-thalassemia is a genetic disorder that affects the human haemoglobin beta (HBB) gene 
that presents over 200 distinct point mutations and occasionally some deletions182. These point 
mutations frequently happen in an intron, leading to abnormal splicing. β-thalassemia is 
characterized by reduced, abnormal or absent synthesis of β-globin chains182. Patients 
homozygous (β-thalassemia major) have the most severe form of this disease, causing ineffective 
erythropoiesis and hepatosplenomegaly, leading to severe anaemia and typically need recurrent 
iron chelation and transfusions183. 
Currently, the only available cure for this disease is transplantation of hematopoietic stem 
cells when there are available donors with matching histocompatibility183. Until now, a patient 
with HBE1-β-thalassemia, who had a normal HBB gene delivered through the use of a lentiviral 
delivery vehicle into his hematopoietic stem and progenitor cells (HSPC) has not needed 
additional blood transfusions to treat his condition184. Nevertheless, gene therapy that involves 
viral vectors has serious limitations and possible harms as these vectors can integrate randomly 
into numerous locations of the genome of the treated patient, as already observed in other 
genetic disorders185,186. 
In a recent study183, the combination of CRISPR/Cas9 to cleave the HBB gene and the 
piggyBac transposon (a mobile genetic element that efficiently transposes between vectors and 
chromosomes) to select for homologous recombination events, efficiently corrected two 
different β-thalassemia mutations and converted homozygous β-thalassemia to the 
heterozygous states in induced pluripotent stem cells (iPSCs) from β-thalassemia patients183. The 
research team did not observe off-target effects in the treated iPSCs, the karyotypes were normal 
and the cells preserved full pluripotency. They also observed that iPSCs that had been successfully 
edited showed an improved HBB expression following differentiation into erythroblasts, when 
compared to their parental cell line. These corrected iPSCs display normal function and could 
potentially provide a source of cells for transplantation in patients, offering a new strategy to 
cure this disease183. 
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CRISPR Therapeutics, a company founded by Rodger Novak, Emmanuelle Charpentier and 
Shaun Foy in November 2013, is developing a treatment of both Sickle cell disease and β-
thalassemia called CTX001187. CTX001 is a therapy that is performed ex vivo, where the patient is 
the source of the autologous cells that are collected. The CRISPR/Cas9 system is then used on the 
harvested cells to perform a unique genetic change with the goal of obtaining a boost in fetal 
haemoglobin present in the donated blood cells of the patient. Subsequently, the previously 
harvested cells are reintroduced into the patient’s circulation with the hope that they 
differentiate into fetal haemoglobin rich erythrocytes, circumventing the deficit of haemoglobin 
that these illnesses originate187. CTX001 is anticipated to enter clinical trials in 2018 in Europe for 
β-thalassemia187. 
 
2.2.2 Cystic Fibrosis 
 
Cystic fibrosis (CF) is a genetic disease that affects the mucus glands and is generally a 
progressive, chronic and life-threatening illness. It mainly affects young people’s digestive and 
respiratory systems, while it can also possibly involve the reproductive system and sweat 
glands188. Patients that suffer from this genetic disease normally lose high levels of salt through 
sweat resulting in an unbalanced sum of minerals in the blood that can originate irregular heart 
rhythms. Additionally, the affected patients have uncommonly thick mucus that can accumulate 
in lungs and intestines. These disease traits are responsible for inadequate growth, 
malnourishment, breathing difficulties, recurrent infections of the respiratory system, and 
ultimately can lead to permanent lung damage188. In developed countries, CF patients have an 
expected lifespan of 42 to 50 years, where respiratory complications account for approximately 
80% of deaths189. 
This genetic disorder is caused by mutations in the pair of copies of the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene that produces the CFTR protein and is 
hereditary in an autosomal recessive way189. People that have one copy of the gene that is 
operational are considered carriers of the CF gene but display normal function of the mucus 
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glands. More than 1500 CFTR mutations have been identified, but only the functional importance 
of a small number is known. The absence of phenylalanine at position 508 (Phe508del, also 
known as F508del), accounts for about two-thirds of mutated alleles in northern European and 
North American populations189.  
Cystic fibrosis has no cure at the moment but management of its symptoms and reduction 
or even prevention of future complications is possible189. Treatment for associated problems may 
include: antibiotics, digestive enzymes, airway clearance techniques, inhaled hypertonic 
saline and salbutamol, vitamin supplementation, bronchodilators, steroid medication and 
ultimately lung transplantation189. 
CRISPR/Cas9 genome editing was successfully employed in a culture of intestinal stem 
cells of people afflicted by CF and the CFTR locus was efficiently corrected by homologous 
recombination190. The corrected gene was expressed and fully functional, CRISPR/Cas9-mediated 
repair of the CFTR locus restored cAMP-induced intestinal stem cell organoid swelling, lost in 
CFTR mutant organoids of cystic fibrosis patients190. This study demonstrated the possibility of 
gene correction mainly in adult stem cells derived from patients with a monogenic hereditary 
defect, and combined with a previous study, in which in vitro expanded organoids were 
transplanted into the colons of mice successfully191, provides a potential strategy for future gene 
therapy in cystic fibrosis patients190. 
 
2.2.3 Duchenne Muscular Dystrophy  
 
Duchenne muscular dystrophy (DMD) is a genetic disorder that is known for its 
progressive muscle deterioration and associated weakness. The disorder is X-linked recessive and 
is caused by a mutation in the gene for the protein dystrophin (DMD gene), which is important 
to maintain the muscle fibres membrane. This protein is located primarily in skeletal muscles and 
in cardiac muscle192.  
People affected with DMD show an elevated level of the enzyme creatine kinase in 
their blood. Currently, there is no cure for muscular dystrophy192. However, some symptoms can 
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be attenuated using surgery to correct common issues related to DMD such as spinal curvature 
caused by scoliosis or deformities of the foot and physical therapy braces, while those affected 
with deteriorated muscles responsible for breathing might benefit from assisted ventilation. 
Muscle deterioration can be slowed down by using steroids, while immunosuppressants can be 
used to postpone injury to muscle cells that are dying and, finally, anticonvulsant medication has 
the ability to control some activity of the muscles and seizures192. 
CRISPR/Cas9 has been successfully applied by Li et al.193 to restore the dystrophin protein 
in DMD patient derived iPSCs. The team performed three correctional methods, exon skipping, 
frameshifting, and exon knock-in, and found the latter to be the most effective approach. 
Additionally, they differentiated the CRISPR/Cas9 edited iPSCs into skeletal muscle cells and 
confirmed the expression of dystrophin protein. Similarly, several independent groups194–197 used 
adeno-associated virus to deliver CRISPR/Cas9 system into the DMD mouse model to remove the 
mutated exon 23. This experiment included local and systemic delivery resulting in deletion of 
exon 23 and consequently restoring the expression of the dystrophin gene in myofibers and 
cardiomyocytes. More recently Long et al.198 myoedited iPSCs from multiple patients with DMD 
genes that harbour point mutations, large deletions or duplications and their team was able to 
reinstate the expression of the dystrophin protein with relative success in derivative 
cardiomyocytes. Myoediting of mutations responsible for the disease in three-dimensional 
engineered heart muscle (EHM), resulted in the reinstatement of the protein expression and the 
matching mechanical force of contraction. It was enough to amend only a subsection of 
cardiomyocytes from the mutant EHM phenotype in order to improve it to normal control levels. 
These reports attest to the capacity of CRISPR/Cas9 mechanism as a future therapy for DMD 
patients. 
 
2.2.4 Huntington’s Disease  
 
Huntington's disease (HD) is a progressive autosomal dominant neurodegenerative 
disorder caused by mutations in the huntingtin (HTT) gene199. The mutations involve the 
expansion of the CAG repeats in the first exon of the HTT gene that provides the genetic 
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information to produce the huntingtin protein. Generally, in healthy people the HTT gene has 10 
to 35 repetitions of the CAG segment199. However, an increase of these CAG segment repetitions 
that ranges from 36 to over 120 times is observed in people affected by Huntington’s disease. It 
has been observed that patients who have 36 to 39 CAG repeats might possibly show symptoms 
and signs of the disease, while those that possess more of these repeats most certainly acquire 
the illness200. The expansion of the CAG segment results in an abnormal long huntingtin protein. 
This lengthened HTT protein is divided into toxic small fragments that have the ability to remain 
jointly and gather in neurons, resulting in a disturbance of the standard functions of these 
specialized cells199.  
The dysfunction and death of neurons cause the symptoms of Huntington disease such as 
loss of cognitive skills, depression, involuntary movements, and alterations in personality as well 
as difficulty in thinking. Symptoms generally start between age 30 to 45, and life span is around 
15 to 20 years after the first signs appear. There is no cure for Huntington’s disease, in later stages 
of the disease full time care is necessary and treatments can ease some of the symptoms199. 
Dabrowska et al.201 proved that the CAG repeat can be precisely excised from the HTT 
gene using the Cas9 nickase strategy. The team used as a model fibroblasts of a HD patient with 
various numbers of CAG repeats. Excision of the repeat disabled the HTT gene and inhibited 
huntingtin synthesis. Since Cas9 nickases are specific and reliable this approach may lead to the 
future cure of Huntington’s disease. 
 
2.3 Antibacterial therapy 
 
Antibacterial agents obstruct the proliferation of bacteria and by interrupting vital 
bacterial cellular functions they can quickly kill them. Most bacteria are typically vulnerable to 
solely a restricted variety of antibacterial agents and possess an intrinsic ability to withstand the 
therapeutic effect of others, also known as resistance. Additionally, bacteria can obtain 
resistance to one or more antibiotics that would usually have an effective therapeutic effect. 
Acquired resistance can arise by mutations in genes often associated with the mechanism of 
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action of the compound and acquisition of foreign DNA coding for resistance determinants 
through horizontal gene transfer. Unfortunately, some types of bacteria are able to acquire 
resistance to multiple drugs which, in extreme cases, can ultimately result in bacteria that show 
resistance to most or all of the agents that would commonly be used to fight them202. 
Whenever an antibiotic is used to treat an infection, there is possibility that the agent will 
select, in the population of bacteria infecting the organism, for bacteria that demonstrate to have 
acquired a resistance to the antibiotic in question, therefore causing an unsolved infection in 
supposedly treated patient. A further selection of resistant bacteria may also occur in the 
patient’s commensal flora, resulting in colonisation by resistant bacteria, which possibly will be 
accountable in the future for a different infection at the same or alternative location in the body. 
The resulting resistant bacteria will have the opportunity to spread to other people, especially 
within hospitals leading to growing rates of resistance to antibiotics203. The causes of the fast 
spreading of antibiotic resistance are identified as the over-prescribing of antibiotics, patients 
not taking antibiotics properly, an unnecessary use in agriculture, poor infection control in clinics 
and hospitals, a lack of rapid laboratory tests and poor hygiene and sanitation practices204. 
Each year, infections caused by multidrug-resistant bacteria in the European Union (EU) 
result in extra healthcare costs and productivity losses of at least 1.5 billion euros and is even 
responsible for 25 000 deaths205. The World Health Organization (WHO) has named antibiotic 
resistance as one of the three most important public health threats of the 21st century206. 
However, there has been a lack of research and development for new antibiotics, in the last 
decades, as the identification of new active compounds became harder and the attention of 
pharmaceutical companies shifted to more profitable investments205–207. 
Several studies have demonstrated that CRISPR-Cas systems can offer a promising 
solution to overcome current antibiotic resistance while even having a possible better 
selectivity112,208,209. 
Gomaa et al. 209 have showed in their article that they could effectively and specifically 
target bacterial genomes by using CRISPR/Cas systems resulting in a significant elimination of 
distinct strains and species of bacteria. They utilized as a model the bacteria Escherichia coli and 
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a type I CRISPR/Cas system for the bacterial genome targeting. Their team discovered that the 
removal of bacteria could be produced by using either imported or native systems and that the 
transcriptional activity, genomic location and strand of the target sequence didn’t influence the 
effectiveness. Moreover, the crRNAs targeting was precise enough to easily discriminate 
between even vastly similar strains in mixed or pure cultures. However, an appropriate delivery 
vehicle was lacking, exposing an obstacle to overcome if control of bacterial populations in 
diverse ecological niches and scientific fields were to be used. 
Later, Citorik et al.208 and Bikard et al.112 reported the use of CRISPR-Cas systems as 
antimicrobials in which they overcame the delivery vehicle challenge using phagemids, plasmids 
with phage packaging signals210. Citorik’s team used Escherichia coli as a model, whereas Bikard 
and colleagues used Staphylococcus aureus. The bacteria these teams used are particularly 
pertinent since they both have described resistances to antibiotics211, predominantly the 
multidrug-resistant Staphylococcus aureus (MRSA)212.  
The bacterial genome was targeted by the engineered phagemids, resulting in a fast and 
comprehensive elimination after an increase in the quantity of phagemid employed. Additionally, 
the packaged phagemids were equally used in both studies to target plasmids that had acquired 
resistance to antibiotics, resulting in the effective elimination of the plasmids112,208. Citorik et 
al.208 also investigated conjugation as a means of delivery, but the transfer efficiency was too low 
to substantially reduce cell counts. 
Both Citorik’s208 and Bikard’s112 teams used mixed bacterial communities and were able 
to eradicate solely the targeted strains of bacteria whereas other strains were unaffected. The 
team led by Citorik was also capable of identifying a change in a single base-pair when looking at 
two different bacteria strains, thus underlining the target accuracy. 
The research of both teams was additionally enriched by performing studies in vivo. 
Citorik et al.208 used larvae of Galleria mellonella as an infection model for enterohemorrhagic E. 
coli, while Bikard et al.112 used fluorescence to their advantage. Their team used a co-culture of 
two strains of S. aureus in a model of skin infection in mice in which one strain was fluorescent 
and the other was not, with the former being the target of the technique employed. They equally 
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demonstrated that the target strains were substantially harmed by the applied phagemids which 
was verified by an improved survival of the larvae or a decrease in fluorescent S. aureus present 
on the skin of the animal112,208. 
The studies mentioned above demonstrate the plausibility of using CRISPR-Cas systems 
as antibacterial agents, particularly in antibiotic resistant strains. While these systems have 
several advantages over traditional antimicrobials, the authors also recognize that to exploit its 
capabilities, the development and optimization of delivery strategies is needed112,208,209. 
Regardless of the challenges ahead, CRISPR seems to be an interesting and worthwhile 
option to explore as a novel antibacterial agent.  
 
2.4 Oncology 
 
Cancer is a group of diseases that is characterized by an abnormal cell growth in any body 
part, which can grow outside of their normal borders, invade adjacent structures and, 
consequently, spread to other tissues and organs (metastasizing)213,214. Cancer cells are less 
differentiated than normal cells and do not possess specific functions that mature cell types have 
and, consequently, continue to divide. In addition, cancer cells are able to bypass checkpoints 
that regulate cellular growth and might impact normal molecules, cells and blood vessels that 
are around a tumour and feed it213. During the mestastatic process, cancer cells are able to 
modulate the microenvironment by releasing extracellular signals, by inducing peripheral 
immune tolerance and promoting tumour angiogenesis 213,215. 
According to the World Health Organization214, cancer is a leading cause of death globally, 
that accounts for close to 9 million deaths which translates to be the cause of nearly 1 in 6 deaths. 
Additionally, cancer has an economic impact that is considered to be noteworthy and growing, 
with an estimated US$ 1.16 trillion of total annual economic cost216. 
Cancer is a genetic disease that starts with the conversion of a normal cell into a tumour 
cell during a multi-step process213,214.  The transformation of a benign mass into a tumor mass is 
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the result of the interaction between external agents and the patient genetic background. The 
external agents can be classified in physical, chemical or biological carcinogens. Common physical 
external agents include ultraviolet (e.g. the sun) and ionizing radiation, while asbestos and 
components of tobacco smoke are ordinary chemical carcinogens. Finally, biological agents 
include infections from some bacteria, parasites or viruses213,214. Some of these were discussed 
in previous chapters. 
The genetic modifications that are responsible for the development of cancer usually 
target DNA repair genes, proto-oncogenes and tumor suppressor genes. Usually, proto-
oncogenes are responsible for regulating cell growth and division but when these genes acquire 
mutations and become unusually more active, thus promoting more cell growth and division, 
they convert into oncogenes and contribute for cancer development. This enables cells to grow 
and survive in conditions that otherwise would not. Similarly, tumor suppressor genes are equally 
responsible for controlling cell growth and division by repressing cell division and inducing DNA 
repair or apoptosis. Cells that hold certain alterations in these genes may divide irrepressibly. 
DNA repair genes are responsible for fixing DNA that got damaged by the agents mentioned 
earlier and cells that possess mutations in these genes are predisposed to acquire further 
mutations in other genes213. 
The genetic modifications can occur by distinct mechanisms and at independent levels. 
Chromosomes can be entirely added or deleted due to misfunctions in mitosis. However, 
mutations that change the nucleotide sequence of genomic DNA are more common217,218.  
Large-scale mutations include the addition or deletion of a portion of a chromosome. 
Gene amplification occurs when a cell gets copies of a small chromosomal locus, which normally 
contains several oncogenes and some adjacent genetic material. Translocation happens when 
two distinct chromosomal regions become unusually fused. On the other hand, small-scale 
mutations include point mutations, insertions and deletions that can occur either in the promoter 
region of a gene and, consequently, affect its expression, or in the coding sequence of the gene 
and alter the function or stability of its protein. Disruption of a gene can also result from an 
integration of genomic material from a virus that, consequently, lead to expression of viral 
oncogenes in the affected cell217,218. 
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Current treatments of cancer depend on a correct diagnosis for the adequate and 
effective treatment since every cancer type requires a specific treatment regimen that includes 
one or more modalities such as chemotherapy, radiotherapy, surgery, immunotherapy, targeted 
therapy, hormone therapy and stem cell transplant214,219. The primary goal of treatment is usually 
to cure cancer or to considerably prolong life. Another important factor is improving the cancer 
patient’s quality of life which can be achieved by supportive or palliative care and psychological 
support214. 
Sadly, the existent therapeutic arsenal for cancer has limitations in its curing ability and 
many reported side-effects and toxicity217,220. In this regard, CRISPR/Cas9 may present a new and 
exciting opportunity in the battle against this devastating disease. Since cancer arises from the 
transformation of normal cells into tumor cells through modification of various but specific 
genes, CRISPR/Cas9 can be used to study these alterations or to restore the normal function of 
these cells and consequently halt the spread of cancer, ultimately leading to a clinical cure of the 
disease. 
CRISPR/Cas9 uses in cancer research ranges from functional validation of genes involved 
in the progression of cancer to the modelling of the disease and new therapeutic designs221. From 
research on a small scale222–224 to high-throughput screens of gene function225–227, this technique 
has unravelled new knowledge about the development of cancer and the metastatic process and 
even guided towards the identification of novel potential therapeutic targets. 
CRISPR/Cas9 can be used in screens, as it is a powerful functional genomic tool that aids 
on the discovery of new targets for cancer therapy. Pooled screening with CRISPR/Cas9 requires 
a cell population with a diversity of gene knockouts to be generated in a multistep process with 
the main goal of identifying genotype-specific vulnerabilities228. The identified essential genes 
can turn out to be potential drug targets228. When compared to other methods, CRISPR was 
shown to be more sensitive in detecting essential genes229, leading to more large-scale 
CRISPR/Cas9 screens being conducted to systematically discover essential genes across several 
cancer cell lines230–232. 
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A complementary screening approach to identify new drug targets relies on the concept 
of synthetic lethality which appears when the expression of two or more genes have a 
combination of insufficiencies that ends up in the death of the affected cell, while an insufficiency 
in a single gene does not228,233. In cancer, this means that previously non-essential genes can 
become essential due to the loss of a specific tumor suppressor or the activation of an 
oncogene233. Due to the increasing knowledge on the structural alterations of cancer, this 
method could vastly expand the spectrum of potential drug targets228. Several CRISPR/Cas9 
screens have been carried out to identify synthetic lethal interactions234–236 but a future challenge 
will be to unravel the underlying molecular mechanisms and identify synthetic lethal interactions 
that can be translated into therapies228. 
CRISPR/Cas9 screening can also be used to study chemico-genetic interactions, which 
gives insights into how cancer responds to drug treatment. Using a drug as perturbation in a 
pooled CRISPR screening, allows the identification of gene knockouts that act synergistically with 
or confer resistance to the agent228. Several studies have used this method to identify synergetic 
or resistant interactions of anti-cancer drugs and genes that modulate cellular response to 
specific drugs237–240. Similarly, this approach has been used to explore the mode of action of 
poorly characterized anti-neoplastic drugs such as apilimod241 and in a combinatorial screening 
in which two predefined sgRNAs are encoded in lentiviral plasmids that allows not only the 
dissection of genetic interaction of pairwise gene knockouts, but also enables identification of 
synergistic drug targets242,243. 
Most of the human genome consists of non-protein coding regions that contain many 
regulatory elements such as enhancers or non-coding RNAs. Since the expression of these non-
coding RNAs is known to be deregulated in cancer244 and the transcription of oncogenes can be 
controlled by near and distant enhancer elements245, the comprehensive understanding of non-
coding elements will provide deeper insights into cancer biology. In this regard, CRISPR/ Cas9 has 
been shown to be a strong screening tool for the identification of non-coding elements such as 
enhancer regions246,247 and/or other functionalities248–251. 
CRISPR/Cas9 can be used to generate organoid cancer models by first isolating and 
cultivating stem cells from adult tissues and later stimulating them with tissue specific growth 
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factors, thus differentiating and forming organoids in a cell culture dish. This opens the possibility 
to culture both healthy and cancerous tissue which in turn enables the study of tumor 
development and progression in vitro228. In this regard, The CRISPR/Cas9 system has been used 
in several studies221,228 as a tool to transform the healthy human organoids into their cancerous 
counterparts by disrupting both tumor suppressor genes and oncogenes which, ultimately, 
provides the opportunity to unravel the responsible mechanisms of cancer formation228. 
Additionally, CRISPR/Cas9 can be used for in vivo screening, where factors that influence 
the microenvironment are present. In vivo can be either achieved by implanting ex vivo edited 
cancer cells or by delivery of CRISPR/ Cas9 components to mouse tissues, thereby generating 
tumors221,228. The transplantation of ex vivo CRISPR edited cells enables screening of sgRNAs with 
high-throughput which allows identification of key genes in cancer development. This method 
has already been applied in several cancer models such as lung226, liver252 and colon253 cancer 
cells. The direct in vivo approach of genome editing is a potent way to study the effect of genetic 
alterations on carcinogenesis in a native tissue microenvironment228. Several studies221,254–259 
have demonstrated the applicability of this method where the delivery of sgRNAs and Cas9 
targeting oncogenes and tumor suppressor genes resulted in the formation of the desired cancer 
model yielding new insights into the function of cancer-associated genes. 
Gene therapy trials have been previously performed in earlier years. However, they have 
mainly been unsuccessful for several reasons such as: somatic silencing of gene products, host 
immune response, viral vectors and mutagenesis260. Fortunately, the new technologies of gene 
editing which includes CRISPR/Cas9 may soon overcome some of the current obstacles and allow 
permanent modification of somatic cells228. 
The first clinical trial using CRISPR for cancer therapy took place at West China Hospital, 
Sichuan University in Chengdu in 2016261,262. It is a non-randomized, open-label phase I study 
where the safety of programmed cell death protein-1 (PD-1) knockout engineered T cells ex vivo 
is evaluated in treating metastatic non-small cell lung cancer that has progressed after all 
standard treatments261. PD-1 is a T-cell receptor responsible for the inhibition of T-cell activation, 
thus regulating immune tolerance and decreasing autoimmune reactions. However, this also 
allows cancer to escape an immune response263. In this study, patients provide a sample of 
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peripheral blood lymphocytes and the T-cells are later edited ex vivo by the CRISPR/Cas9 system 
to obtain PD-1 KO. The edited lymphocytes are then selected, expanded and subsequently 
infused back into the patients261. Similarly, four other trials are applying the same concept of PD-
1 knockout for the treatment of other cancer types, including bladder, esophageal, prostate and 
renal cell cancer262, while another registered phase I/II trial adds PD-1 knockout to EBV-specific 
autologous T-cells for the treatment of EBV positive cancers264. The first clinical trial using 
CRISPR/Cas9 for cancer therapy outside of China was approved in the Unites States of America 
(USA) in the University of Pennsylvania265. It is a phase 1 trial of autologous T Cells engineered to 
express NY-ESO-1 TCR and CRISPR gene edited to eliminate endogenous T cell receptor (TCR) and 
PD-1 to test whether NY-ESO-1 is expressed on certain tumor tissues266. 
Another ex vivo method is the generation of chimeric antigen receptor (CAR) T-cells with 
CRISPR/Cas9. CARs are engineered receptors that are transduced into T-cells and are able to 
reprogram these cells to target malignant cancer cells. In a preclinical study, they directed a CAR 
to the T-cell receptor α constant (TRAC) locus using CRISPR/Cas9 produced T-cells with 
immensely enhanced activity against tumours compared to conventionally produced CAR T-cells 
using randomly integrating vectors267. CRISPR/Cas9 is also being used in two distinct clinical trials 
to generate CAR T-cells. One of them is a phase I/II study of universal CRISPR/Cas9 gene-editing 
CAR-T cells targeting CD19 in patients with relapsed or refractory CD19+ leukemia and lymphoma 
where they will test whether it can evade host-mediated immunity and deliver antileukemic 
effects without graft-versus-host disease268. To overcome the fact that that a subset of patients 
in this trial relapsed due to the loss of CD19 in tumor cells, another phase I/II study has started. 
This new trial pretends to evaluate if using this CRISPR/Cas9 gene-editing CAR-T cells targeting 
CD19 and CD20 or CD22 would recognize and kill the CD19 negative malignant cells when they 
express CD20 or CD22269. 
The only in vivo registered phase 1 clinical trial pretends to use TALEN or CRISPR/Cas9 
plasmids targeting HPV16 and HPV18 E6/E7 DNA (previously discussed in chapter 2.1.4). The 
constructs are delivered with a gel that is locally applied to the HPV infected cervix and the safety 
and dosing regimen will be determined. Likewise the change of HPV 16 or 18 DNA titers, as well 
as cervical cytology and histology will be evaluated270. 
CRISPR: applications in human pathologies and future prospects 
 
 44 
CRISPR/Cas9 is proving to be a powerful tool in both studying and providing potential new 
therapies for cancer. Combined with existing techniques and therapies, it might provide an 
additional hope for those affected by cancer as it has shown promising results. Improvements in 
the specificity of Cas9 for targeting specific genomic regions without off-target effects and more 
efficient delivery methods to target specific tumours or organs with CRISPR/Cas9 constructs will 
certainly spark the interest of further developing in vivo gene editing clinical trials in the future228. 
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3. LIMITATIONS 
 
Despite the countless potential applications of the CRISPR/Cas9 system in human 
pathology, there are some important issues that need to be addressed before its application for 
clinical use, such as off-target mutations, PAM-dependence and delivery methods of 
CRISPR/Cas9271. 
Generally, large genomes hold several sequences of DNA that are either vastly 
homologous or equal to target DNA sequences. CRISPR/Cas9 can cleave both these sequences, 
which can consequently lead to off-target mutations that can result in the transformation or 
death of the cell2,271. The extent to which a given guide sequence exhibits off-target activity 
depends on a combination of factors including the abundance of similar sequences in the target 
genome2 and the dosage of CRISPR/Cas9, which should be carefully controlled272,273.  
Several efforts to reduce the cellular toxicity of CRISPR/Cas9, by reducing the off-target 
mutations have been reported2,63,272,274,275. Moreover, Cas9 can be converted into nickase to 
assist in reducing the mutations in undesired sites, without changing the effectiveness of the 
desired targeted cleavage executed by CRISPR/Cas963. 
One of the biggest lasting limitations of the CRISPR/Cas9 system is effectively delivering 
its endonuclease into tissues or cells in order to accomplish the desired therapeutic result. A 
promising approach to deliver nucleases into cells is by transfecting the nuclease and gRNA 
expression-cassette bearing plasmid DNA. Regardless of this technique being easy to 
implement, it has not been extensively employed due to several shortcomings such as 
cytotoxicity related to the use of DNA and bacterial DNA sequences in plasmid backbones, low 
transfection efficiency of primary cells and a possibility of plasmid fragments being arbitrarily 
introduced into the gene65,276. 
It is preferred to use vectors based on adeno-associated virus in somatic gene therapy 
since this type of vectors are not pathogenic, only induce a residual immune system response 
and can target non-dividing cells65,277. Nevertheless, as previously mentioned in earlier 
chapters, these vectors have limitations on the amount of DNA that can be cloned into their 
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backbones, where the coding sequences of Cas9 and sgRNA barely fit. As such, smaller Cas9 
variants82 and several systems to create split Cas9 enzymes83–85 have been developed but both 
suffer from reduced efficacy82–85. Alternatively, Cas9 can be delivered to cells as RNA transcripts 
of the gene via microinjection87–89, electroporation90,91 or in in the form of integrase defective 
lentiviral particles93,94. 
The development of non-DNA-dependent alternatives including RNPs paved the way for 
novel methods for delivery in gene therapy, allowing effectively a lot of genomic modification 
through microinjections and electroporation90,95,96, lipid-mediated transfection97 or other non-
standard techniques98–101. When comparing delivery methods of previously assembled 
complexes of protein and RNA with nucleotide delivery methods based on vectors for genome 
targeting by CRISPR, the former displayed less cell toxicity and enhanced reliability resulting in 
the elimination of the safety issues related to the insertion of foreign DNA65. 
Despite recent advances in new delivery methods, the development and optimisation of 
efficient delivery vehicles is needed before further clinical consideration of the CRISPR/Cas9 
system. 
Hypothetically, CRISPR/Cas9 can be used to target any DNA sequence via engineered 
customizable gRNA but for this system to be precise there must be a PAM sequence composed 
of two to five nucleotides that is positioned directly downstream of the target sequence. 
Furthermore, it is compulsory that the gRNA is complementary to the target sequence27. The 
PAM dependence of CRISPR/Cas9-mediated DNA cleavage constrains the frequencies of 
targetable sites in genomes but simultaneously increases the specificity of CRISPR/Cas9. 
Therefore, there should be less observed off-target mutations in CRISPR/Cas9 systems that 
demand longer PAM sequences47. 
Conceivable genome editing in the human germline has seen ethical apprehension, as this 
is the transmittable genome to future generations from different origins including embryos, 
fertilized eggs or gametes. The reasoning behind these concerns stems from the fact that editing 
germline cells can in one hand, have the expected gene correction and on the other hand 
induce mutations in undesired locations that will be later transmitted to innumerable 
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generations. Therefore, an ethical discussion has arisen on whether the benefits compensate 
the associated hazards of using CRISPR/Cas9 as a method to genetically edit the human 
germline. Additionally, informed consent has been object of doubt as this is unobtainable by 
the descendants that acquire unwanted effects of the application of this technique and finally 
it is ambiguous who is accountable for the possible genetic harm that is transmitted to 
numerous generations278. 
Lastly, CRISPR/Cas9 could be used for purposes other than therapeutic ones including 
individual enhancement which raises another ethical concern. This could be attained by editing 
germ or somatic cells using CRISPR/Cas9 and selecting favourable phenotypic features such as 
improved intellectual or athletic performance which could ultimately lead to unfairly designed 
offspring. This in turn may have a profound social impact. What are the requirements to choose 
who can benefit from editing the genome, who makes that decision, how do we obtain an 
informed consent from the beneficiary, are some of the pertinent questions that come along 
with the beauty of manipulating genes using CRISPR/Cas9 technique278. 
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4. CONCLUSION 
 
Currently, many diseases affecting mankind still do not have a clinical cure and finding a 
cure for these pathologies has shown to be quite challenging. In this regard, genome editing is 
an interesting field of study that has been advancing at a remarkable pace to achieve new 
therapeutic treatments for many of these pathologies. 
Genome editing can be accomplished through engineered, programmable and highly 
specific nucleases such as meganucleases, Zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs) and more recently CRISPR/Cas9. The latter technique has quickly 
surpassed all the others, owing to its easy and non-time-consuming customization and its simple 
and highly efficient mechanism of editing compared to the other methods. 
As previously discussed during this work, CRISPR/Cas9 has been the subject of an 
increasing number of studies in numerous different fields, ranging from medicine to agriculture, 
with diverse applications such as controlling transcription, modifying epigenomes, conducting 
genome-wide screens, manipulating biological circuits facilitating the generation of synthetic 
materials, correcting gene mutations and controlling the expression of entire genes. The 
possibilities of this newfound technique seem to be endless. Specifically, the use of the 
CRISPR/cas9 system in therapeutic research of incurable diseases such as some viral diseases, 
genetic disorders and different types of cancers has refreshed the hope of finding cures to many 
of the debilitating diseases discussed in this work as it has shown promising results. 
However, CRISPR/cas9 also possesses some limitations which hinder the progression of 
its use in clinical research. One of the limitations concerns the possible off-target mutations that 
can result in cell death or transformation. Thus, before CRISPR/cas9 can be further used in clinical 
research, the specificity and possible cellular toxicity needs to be addressed. Another issue of this 
powerful editing technique seems to lie in the delivery process of the CRISPR/cas9 system into 
tissues or cells to achieve its therapeutic effect. While adeno-associated virus based vectors are 
favored for use in somatic gene therapy, they are limited by their packaging limit and, even 
though ways to circumvent the AAV shortcomings have been investigated, they suffered from 
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reduced efficacy. Alternatively, RNA transcripts via microinjections, electroporation or in the 
form of defective lentiviral particles have been tested but presented its own flaws. Finally, RNPs 
paved the way for novel methods for delivery with improved fidelity and reduced cell toxicity. 
Nevertheless, despite the recent advances in new delivery methods, the development and 
optimization of efficient delivery vehicles is needed before further clinical consideration of the 
CRISPR/Cas9 system. Finally, ethical concerns have been raised regarding the use of CRISPR/cas9 
in the human germline, questioning if the benefits indeed outweigh the risks and raising the 
issue of informed consent and the possibility of using it as an enhancement agent. 
The future of CRISPR/Cas9 seems promising with seemingly endless possibilities and 
applications of this new genome editing technique. Nevertheless, some flaws must be addressed 
before its further use in clinical research. The specificity, safety and toxicity must be closely 
controlled and improved so that the benefits outweigh the risks to test and later use it on humans 
as a novel therapeutic agent. Concluding, it is worthwhile to investigate further the CRISPR/Cas9 
system as it may turn out to be the long-awaited cure to many incurable diseases with a great 
impact on humankind.  
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